In the News
Q&A: BARDA Director Rick Bright Discusses New Programs, Focus on Diagnostics
Rick Bright joined the Biomedical Advanced Research and Development Authority in 2010 following a scientific career addressing influenza at the US Centers for Disease Control and Prevention and at PATH, plus a stint in industry at a vaccine development firm. Now a 12-year-old agency, BARDA was always intended to be...
Execs On The Move: Marketing And Sales Appointments At Quest, SomaLogic And Immunexpress
Quest Diagnostics and SomaLogic, a protein biomarker discovery and diagnostics company, will each bring on a new chief commercial officer; Immunexpress, a sepsis diagnostics firm, hired a VP for market development and commercial operations; and more.
Surviving sepsis: Beth’s story
There are some unspoken rules in the TV news business, like always assume the microphone is hot and stay out of other photographers’ shots. Another is to keep the story succinct. Even on a one-hour broadcast, a general report may last a minute and a half, possibly two. But there...
Novacyt, Immunexpress Extend Sepsis Assay Development Partnership
French diagnostics firm Novacyt said today that its molecular testing division Primerdesign has extended its sepsis assay development contract with Immunexpress. Specific terms of the deal were not disclosed. Novacyt said the companies have been working together for three years, with Primerdesign providing Immunexpress with assay development services....
Medical Device Daily – Other News to Note
Immunexpress Inc., of Seattle, reported a partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which the Division of Research, Innovation...
Immunexpress Wins $745K HHS Contract for Rapid Sepsis Assay
Immunexpress said today that it has received a funding commitment of $744,739 from the US Department of Health and Human Services (HHS) for the development and commercialization of its SeptiCyte sample-to-result sepsis assay. The RT-qPCR assay, which received US Food and Drug Administration 510(k) clearance in early 2017, is...
Future In A Flash – Rollie Carlson CEO of Immunexpress
As the JP Morgan Healthcare Conference convenes in San Francisco, we’re offering a glimpse into the future of the industry, from the C-suites of the most promising pharma, biopharma, medtech, tech and telehealth companies in the nation. Today we explore the latest trends in rapid diagnostics with Immunexpress CEO, Rollie...
Sepset’s Sepsis Signature
BioCentury Senior Writer Michael Leviten discusses gene expression tests that could speed up diagnosis of sepsis.
Most People Don’t Know What Sepsis Is
September is Sepsis Awareness Month and part of the problem in fighting sepsis is that most people don’t know what it is, reports Westwood One. However, now there may be a faster way to detect it. Sepsis occurs when the body’s efforts to fight an infection trigger inflammation throughout the...
Immunexpress Saving Lives with Improved Sepsis Diagnosis: Interview with Rolland Carlson PhD, CEO
Medgadget editor Tom Peach sat down with Dr.Carlson from Immunexpress to hear more about the company’s first FDA-approved sepsis diagnostic test, SeptiCyte, and what the future of sepsis diagnosis and treatment may look like.
3 Need-to-Know Leaps in Sepsis Care
Rolland Carlson, PhD, CEO of Immunexpress, discusses a different approach to the sepsis battle. Rather than passively chasing pathogens, the Company has developed a test to measure the body's specific immune response to infection by examining biomarkers in the patient's blood.